Cingulate Inc (CING)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$4.24-7.02%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · CING
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and has erratic recent earnings surprises. A fundamental tilt, not a price call.
Model as of 2026-11-05 · Compared with 117 industry peers
CING — officer change
Dated 2026-10-02
Chief Medical Officer — Matthew N. Brams: The filing discloses an amendment to an employment agreement extending a trial period, which is a contractual administrative matter rather than a change in management or a departure.
Why it matters: The FDA asked for more manufacturing details. A resubmission is the next clear step toward a new review.
Supportive ifCingulate files the CTx-1301 NDA again and confirms it meets the FDA's CMC requests.
Worry ifThe company says key CMC work is not done. Or it gives no resubmission update by its next quarterly report.
Why it matters: The FDA's June 2026 letter asked for more manufacturing details, not new safety or efficacy data. The FDA's decision will show if the CMC work fixed those issues.
Watch forThe FDA approves the resubmitted NDA or accepts it for review without new CMC requests.
Also watch forThe FDA issues another complete response letter or asks for more CMC work.
Why it matters: Cingulate is working with Bend Bioscience on manufacturing steps needed for a possible launch. Delays could push back launch readiness.
Supportive ifCingulate says process validation is complete and launch inventory is ready. Or it gives a completion date.
Worry ifCingulate says validation is delayed, launch batches fail, or CMC work is not done.
Why it matters: Cingulate said its cash can fund operations into mid-2027. Rising costs or a shorter runway could lead to more financing needs.
Worry ifCash falls below $20 million before year-end 2026. Or management says its cash runway ends before mid-2027.
Less concerning ifCash stays at or above $20 million at year-end 2026, and management keeps its runway estimate at mid-2027 or later.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$175 on $10,000 · ±1.7% | How much price usually moves either way. |
| Bad day | $690 loss on $10,000 · 6.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,913 loss on $10,000 · 69.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.